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Background: The Daniel Fast is a vegan diet that prohibits the consumption of animal products, refined foods,
white flour, preservatives, additives, sweeteners, flavorings, caffeine, and alcohol. Following this dietary plan for
21 days has been demonstrated to improve blood pressure, LDL-C, and certain markers of oxidative stress, but it
has also been shown to lower HDL-C. Krill oil supplementation has been shown to increase HDL-C.
Methods: We investigated the effects of following a Daniel Fast dietary plan with either krill oil supplementation
(2 g/day) or placebo supplementation (coconut oil; 2 g/day) for 21 days. The subjects in this study (12 men and 27
women) were heterogeneous with respect to body mass index (BMI) (normal weight, overweight, and obese),
blood lipids (normolipidemic and hyperlipidemic), blood glucose (normal fasting glucose, impaired fasting glucose,
and type 2 diabetic), and blood pressure (normotensive and hypertensive).
Results: Krill oil supplementation had no effect on any outcome measure (all p> 0.05), and so the data from the
krill oil group and the placebo group were collapsed and analyzed to examine the effects of following a 21-day
Daniel Fast. Significant reductions were observed in LDL-C (100.6 ± 4.3 mg/dL vs. 80.0 ± 3.7 mg/dL), the LDL:HDL
ratio (2.0 ± 0.1 vs. 1.7 ± 0.1), fasting blood glucose (101.4 ± 7.5 mg/dL vs. 91.7 ± 3.4 mg/dL), fasting blood insulin
(7.92 ± 0.80 μU/mL vs. 5.76 ± 0.59 μU/mL), homeostasis model assessment of insulin resistance (HOMA-IR)
(2.06 ± 0.30 vs. 1.40 ± 0.21), systolic BP (110.7 ± 2.2 mm Hg vs. 105.5 ± 1.7 mm Hg), and body weight (74.1 ± 2.4 kg vs.
71.5 ± 2.3 kg) (all p< 0.05).
Conclusion: Following a Daniel Fast dietary plan improves a variety of cardiometabolic parameters in a wide range
of individuals in as little as 21 days, and these improvements are unaffected by krill oil supplementation.
Trial registration: Clinicaltrial.govNCT01378767
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Type 2 diabetes and cardiovascular disease are two epi-
demics that will grow more prevalent in the near future
[1,2]. Dietary treatments that target the main parameters
associated with type 2 diabetes and cardiovascular dis-
ease – particularly glycemic control, blood lipids, blood
pressure, and body weight – will likely reduce the mor-
bidity and mortality associated with these diseases.* Correspondence: rbloomer@memphis.edu
Cardiorespiratory/Metabolic Laboratory, 161 Roane Field House, University of
Memphis, Memphis, TN 38152, USA
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distribution, and reproduction in any mediumVegan diets have been shown to beneficially modulate
these parameters [3-5].
A recently investigated “Daniel Fast” (a plant-based
dietary plan that prohibits the intake of animal products,
refined foods, white flour, preservatives, additives, sweet-
eners, flavorings, caffeine, and alcohol) was shown to
lower blood pressure, total cholesterol, and low density
lipoprotein cholesterol (LDL-C) [6]. Other improve-
ments associated with this dietary plan include reduc-
tions in malondialdehyde and hydrogen peroxide, as wellntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pacity and nitrate and nitrite (NOx) [6,7].
The Daniel Fast has also been shown to lower high
density lipoprotein cholesterol (HDL-C), although the
reduction in this cholesterol was outpaced by a greater
reduction in LDL-C [6]. Nonetheless, the Daniel Fast
would likely confer even greater cardiovascular benefit if
HDL-C were able to be maintained. A previous study
reported a 43-60% increase in HDL-C in human volun-
teers supplementing with krill oil [8]. Based on those
findings, the purpose of the present investigation was to
compare the effects of krill oil versus placebo supple-
mentation in individuals following a Daniel Fast dietary
plan for 21 days. Nineteen of the 39 subjects who com-
pleted the Daniel Fast supplemented daily with krill oil,
while the remaining 20 subjects supplemented daily with
a placebo. However, krill oil supplementation did not
affect any primary or secondary outcome measure. Con-
sequently, we pooled together the data for subjects in
the krill oil and placebo conditions, and we present the




Subjects were recruited from the Memphis area through
the use of flyers placed on and around the University of
Memphis campus. Eligibility was assessed via question-
naire. Our prior investigation of a 21-day Daniel Fast
indicated that changes in outcome measures in response
to the dietary plan were unaffected by gender, baseline
body weight, or baseline exercise habits [6]. Therefore,
we elected to not place any restrictions on these va-
riables regarding enrollment into the present study. Key
inclusion criteria were men and women between the
ages of 19–65 years with a body mass index (BMI) be-
tween 18–37 kg/m2. Key exclusion criteria were smo-
king, contraindication to krill oil or coconut oil (placebo)
supplementation, pregnancy or desire to become preg-
nant, and unwillingness to follow a vegan diet. As these
exclusion criteria were included in the recruitment flyers,
outside of self-exclusion, none of the individuals that
expressed interest in the study had to be excluded from
participating. Sample size for this study was calculated
based on the changes in total cholesterol and LDL-C that
were observed in our previous investigation of a 21-day
Daniel Fast [6]. Forty-one subjects (13 men and 28
women) were enrolled, but 2 subjects (1 man and 1
woman) withdrew during the intervention phase due to
personal reasons; therefore, 39 subjects were included in
the analysis. Twenty-two subjects were classified as nor-
mal weight (BMI< 25 kg/m2), 9 were classified as over-
weight (BMI 25–29.9 kg/m2), and 8 were classified as
obese (BMI≥ 30 kg/m2). Thirty-three subjects wereclassified as exercise-trained, which was defined as
performing ≥ 2 h/week of combined anaerobic and ae-
robic exercise of moderate to high intensity. On average,
subjects performed 2.1 ± 0.2 h/week of anaerobic exer-
cise for 6.8 ± 1.1 years and 4.7 ± 0.4 h/week of aerobic
exercise for 8.3 ± 1.0 years. Six subjects had elevated BP
(≥ 140/90 mm Hg), 7 subjects had elevated total choles-
terol (≥ 200 mg/dL), and 2 subjects were type 2 dia-
betics. The following medication usages likely affected
some of the outcome measurements in this study: Two
subjects were taking hormone replacements, 2 were taking
hypothyroid medication, 1 was taking an anti-inflammatory,
1 was taking insulin, 1 was taking hyperthyroid medica-
tion, and 1 was taking a stimulant/appetite suppressant.
Failure to exclude individuals taking these medications
during the screening process can be considered a limita-
tion of this study. Subjects were instructed to not con-
sume antioxidant supplements from 2 weeks prior to
beginning the dietary plan until end of study. Prior to par-
ticipation, each subject was informed of all procedures,
potential risks, and benefits associated with the study in
both verbal and written form in accordance with the
approved procedures of the University Institutional Review
Board for Human Subjects Research (protocol H11-14).
Subjects provided written informed consent prior to being
enrolled in the study.
The dietary intervention consisted of only consuming
foods that comply with a Daniel Fast for 21 days. The 21-
day duration was chosen to maximize generalizability –
when motivated by religious reasons, most individuals
follow a Daniel Fast dietary plan for 21 days, although
10- and 40-day Daniel Fasts have also been observed –
and also to allow for a comparison against the findings
from our previous study of the Daniel Fast [6]. No
meals were provided, and energy intake was unre-
stricted. Subjects were permitted to consume any food
or beverage so long as it contained no animal products,
white flour, preservatives, additives, sweeteners, flavo-
rings, caffeine, or alcohol. Special emphasis was made
to instruct the subjects to check the ingredients label of
every food or beverage they planned to consume to en-
sure that it completely lacked any of the proscribed
ingredients mentioned above. As an additional precau-
tion, subjects were provided a list of commonly con-
sumed foods that comply with the Daniel Fast as well as
a second list of commonly consumed foods that do not.
Subjects were also provided a basic recipe guide that
only incorporated ingredients that comply with the
Daniel Fast.
The outcome variables described below were mea-
sured immediately before (day 1) and after following the
Daniel Fast dietary plan (day 22). All data collection oc-
curred between 05:00 and 11:00 hours while subjects
were in a 12-hour post-absorptive state.
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Subjects were randomly assigned to consume one of the
following for the duration of the Daniel Fast: Twenty-
one subjects (7 men and 14 women) were assigned to
orally consume krill oil capsules (NOW Foods, Bloo-
mingdale, IL: 2 g/day in 2 daily dosages of 1 g), and 20
subjects (7 men and 13 women) were assigned to orally
consume placebo capsules (coconut oil; NOW Foods,
Bloomingdale, IL: 2 g/day in 2 daily dosages of 1 g). Spe-
cifically, men and women were alternately assigned to
the krill oil group and the placebo group as they were
enrolled in the study. Both the subjects and the investi-
gators were blind to treatment via the use of coded bot-
tles. A recent investigation examining the safety and
tolerability of krill oil supplementation at 2 g/day for
4 weeks indicated that “krill oil was generally well tole-
rated and did not show evidence of any adverse influence
on safety parameters” [9]. Both of the subjects that with-
drew from the study were in the krill oil group; thus, 19
subjects (6 men and 13 women) in the krill oil group com-
pleted the intervention. Subjects were instructed to con-
sume 1 capsule in the morning with breakfast and another
capsule in the evening with dinner, daily. Capsule counts
upon bottle return at the end of the intervention were
used to determine compliance to the supplementation.
Each capsule of krill oil provided 230–300 mg of Omega-
3 fatty acids, 140–160 mg of EPA, 80–90 mg of DHA, 10–
20 mg of Omega-6 fatty acids, 80–90 mg of Omega-9 fatty
acids, 390–420 mg of phospholipids, and 1.0-1.5 mg of es-
terified astaxanthin.
Blood pressure and heart rate
Subjects were seated in a chair with a BP cuff placed on
their left arm. After a 10-minute period of quiet rest,
two technicians measured heart rate by palpating the ra-
dial artery for 60 seconds. Blood pressure was then mea-
sured via auscultation using a dual-earpiece stethoscope
that allowed for two technicians to listen simultaneously.
Duplicate measures were obtained for both heart rate
and BP, and the average of all measures was used in data
analysis. If values deviated by more than 5 beats/minute
for heart rate or 5 mm Hg for BP, an additional measure
was taken.
Anthropometric variables
Subjects’ height was measured using a stadiometer, and
bodyweight was measured using a calibrated medical
scale. Waist and hip circumference measurements were
obtained using a tension-regulated measuring tape; sub-
jects wore athletic shorts for these measurements. Fat
mass, fat-free mass, total body fat percentage, and trunk-
specific body fat percentage were determined via dual
energy x-ray absorptiometry (Hologic QDR-4500 W)
using a 4-min fan array.Blood collection and biochemical variables
Blood samples that were collected in tubes containing
EDTA were immediately separated via centrifugation at
1500 g for 15 minutes at 4°C for collection of plasma.
Blood samples that were collected in tubes containing
no additives were allowed to clot at room temperature
for 30 minutes and then separated by centrifugation at
1500 g for 15 minutes at 4°C for collection of serum. A
portion of blood samples were analyzed within 1 day of
collection as follows: A complete blood count was per-
formed using an automated cell counter (Coulter
LH750). A comprehensive metabolic panel was obtained
using automated procedures (Roche/Hitachi Modular).
A lipid panel was obtained using enzymatic procedures
(Roche/Hitachi Modular). C-reactive protein was mea-
sured using a high-sensitivity, particle-enhanced turbidi-
metric immunoassay (Roche Integra 800). Insulin was
measured using an immuno-chemiluminescent assay
procedure (Roche Modular E170). The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as: fasting glucose (mg/dL) × fasting insulin
(μU/mL)/405 [10].
The remaining blood samples were immediately stored
in multiple aliquots at −70°C until analysis for the fol-
lowing: Malondialdehyde was analyzed in plasma fol-
lowing the procedures of Jentzsch et al. [11] using
reagents purchased from Northwest Life Science Spe-
cialties (Vancouver, WA). Hydrogen peroxide was ana-
lyzed in plasma using the Amplex Red reagent method
as described by the manufacturer (Molecular Probes,
Invitrogen Detection Technologies, Eugene, OR). NOx
was analyzed in plasma using a commercially available
colorimetric assay kit (Cayman Chemical, Ann Arbor, MI)
according to the procedures provided by the manufac-
turer. Antioxidant capacity was analyzed in serum using
the Trolox Equivalent Antioxidant Capacity assay accord-
ing to the procedures outlined by the reagent provider
(Sigma Chemical, St. Louis, MO). Resistin and adiponectin
were analyzed in serum using an enzyme immunoassay
according to the procedures provided by the manufacturer
(SPI-Bio, Berin Pharma, France).
Dietary records and physical activity
All subjects were instructed to maintain their normal
diet until they began the Daniel Fast. During the 7 days
immediately prior to beginning the Daniel Fast, subjects
recorded all food and beverages consumed. Subjects also
recorded all food and beverages consumed during the
final 7 days of the Daniel Fast. These dietary records
were analyzed using Food Processor SQL, version 9.9
(ESHA Research, Salem, OR). Subjects were instructed
to maintain their normal physical activity and exercise
habits during the entire study period with one exception:
Subjects were instructed to refrain from strenuous
Table 1 Blood pressure and anthropometric data before
and after a 21-day Daniel Fast (Mean values and
standard error of mean (SEM), n = 39)
Variable Pre Post p valuea
Heart Rate (beats/minute) 66.5 ± 1.6 66.5 ± 1.8 0.82
Systolic Blood Pressure (mm Hg) 110.7 ± 2.2 105.5 ± 1.7 0.04
Diastolic Blood Pressure (mm Hg) 71.5 ± 2.3 66.9 ± 1.8 0.11
Body Weight (kg) 74.1 ± 2.4 71.5 ± 2.3 < 0.01
BMI (kg/m2) 25.9 ± 0.7 25.0 ± 0.7 < 0.01
Waist (cm) 86.8 ± 2.0 85.5 ± 2.0 < 0.01
Hip (cm) 101.2 ± 1.8 100.4 ± 1.7 0.01
Waist:Hip 0.85 ± 0.01 0.86 ± 0.01 0.01
Total Body Fat (%) 29.4 ± 1.5 28.8 ± 1.6 0.02
Trunk Body Fat (%) 28.4 ± 1.7 27.3 ± 1.8 < 0.01
Fat Mass (kg) 21.9 ± 1.5 20.8 ± 1.5 < 0.01
Fat-Free Mass (kg) 52.2 ± 2.0 50.8 ± 1.9 < 0.01
a p values represent the results of paired t-tests.
Table 2 Cardiometabolic-, oxidative stress-, and
inflammatory data before and after a 21-day Daniel Fast
(Mean values and standard error of mean (SEM), n = 39)
Variable Pre Post p valuea
Total Cholesterol (mg/dL) 173.1 ± 5.0 146.0 ± 4.8 < 0.01
LDL-C (mg/dL) 100.6 ± 4.3 80.0 ± 3.7 < 0.01
HDL-C (mg/dL) 56.0 ± 2.6 50.9 ± 2.6 < 0.01
Triglycerides (mg/dL) 82.5 ± 7.4 75.2 ± 5.7 0.18
VLDL (mg/dL) 16.5 ± 1.5 15.1 ± 1.1 0.20
LDL:HDL 2.0 ± 0.1 1.7 ± 0.1 < 0.01
Total:HDL 3.3 ± 0.2 3.1 ± 0.1 < 0.01
Glucose (mg/dL) 101.4 ± 7.5 91.7 ± 3.4 0.04
Insulin (μU/mL) 7.92 ± 0.80 5.76 ± 0.59 < 0.01
HOMA-IR 2.06 ± 0.30 1.40 ± 0.21 < 0.01
Resistin (ng/mL) 6.06 ± 0.31 6.72 ± 0.32 < 0.01
Adiponectin (μg/mL) 16.11 ± 0.88 16.49 ± 0.86 0.22
Malondialdehyde (μmol/L) 0.73 ± 0.06 0.71 ± 0.07 0.81
Hydrogen Peroxide (μmol/L) 4.66 ± 0.37 4.47 ± 0.38 0.57
NOx (μmol/L) 19.26 ± 2.56 28.49 ± 3.53 0.01
TEAC (mmol/L) 0.66 ± 0.01 0.62 ± 0.02 0.56
C-Reactive Protein (ng/mL) 1.90 ± 0.60 1.36 ± 0.39 0.14
HOMA-IR, homeostasis model assessment of insulin resistance; NOx, nitrate
and nitrite; TEAC, Trolox Equivalent Antioxidant Capacity.
a p values represent the results of paired t-tests.
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2 assessment days. Subjects were also instructed to re-
frain from alcohol consumption during the Daniel Fast
(as detailed in the dietary guidelines) and also during the
48 hours that preceded day 1.
Compliance to food intake, rating of physical and mental
health, and satiety
At the conclusion of the intervention period (day 22),
subjects completed a questionnaire pertaining to their
experience with the Daniel Fast. Using a scale of 1–10
(1 = as low as possible; 10 = as high as possible), subjects
rated their feeling of physical health and vitality, their
mental health (overall outlook and mood), and their
level of satiety while following the dietary plan. Subjects
also rated their compliance to the Daniel Fast using a scale
of 0–100 (0= complete noncompliance; 100 = complete
compliance).
Statistical analysis
All outcome measures were analyzed using a 2 (condi-
tion) × 2 (pre/post intervention) ANOVA. However, data
for both conditions were subsequently collapsed and ana-
lyzed using a paired t-test. Analyses were performed using
JMP statistical software (version 4.0.3, SAS Institute, Cary,
NC). Statistical significance was set at p≤ 0.05.
Results
Thirty-nine subjects successfully completed the study.
Compliances to the krill oil and placebo supplementa-
tions were 92.4 ± 1.7% and 92.8 ± 2.2%, respectively. No
condition (krill oil or placebo) or interaction effects were
noted for any primary or secondary outcome measure
(p > 0.05). Based on these analyses, data for all variables
were collapsed, analyzed using a paired t-test, and are
presented as pre and post intervention.
Subjects’ self-reported compliance to the dietary plan
was 97.8 ± 0.4%. Subjects’ ratings of physical health and
vitality, mental health, and level of satiety during the
Daniel Fast were 8.3 ± 0.2, 8.6 ± 0.2, and 8.0 ± 0.2,
respectively.
Blood pressure and anthropometric data are presented
in Table 1. Systolic BP decreased (110.7 ± 2.2 mm Hg vs.
105.5 ± 1.7 mm Hg; p= 0.04), while the decrease in dia-
stolic BP was not statistically significant (71.5 ± 2.3 mm
Hg vs. 66.9 ± 1.8 mm Hg; p= 0.11). Body weight
(74.1 ± 2.4 kg vs. 71.5 ± 2.3 kg), fat mass (21.9 ± 1.5 kg vs.
20.8 ± 1.5 kg), and fat-free mass (52.2 ± 2.0 kg vs.
50.8 ± 1.9) each decreased (all p < 0.01).
Cardiometabolic-, oxidative stress-, and inflammatory
data are presented in Table 2. LDL-C (100.6 ± 4.3 mg/dL
vs. 80.0 ± 3.7 mg/dL), HDL-C (56.0 ± 2.6 mg/dL vs.
50.9 ± 2.6 mg/dL) and the LDL:HDL ratio (2.0 ± 0.1 vs.
1.7 ± 0.1) each decreased (all p < 0.01). No changes wereobserved in serum triglycerides or VLDL (both p > 0.05).
Blood glucose (101.4 ± 7.5 mg/dL vs. 91.7 ± 3.4 mg/dL),
blood insulin (7.92 ± 0.80 mg/dL vs. 5.76 ± 0.59 mg/dL),
and HOMA-IR (2.06 ± 0.30 vs. 1.40 ± 0.21) each
decreased (all p < 0.05). Resistin (6.06 ± 0.31 ng/mL vs.
6.72 ± 0.32 ng/mL) and NOx (19.26 ± 2.56 μmol/L vs.
28.49 ± 3.53 μmol/L) increased (both p < 0.05). No
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hydrogen peroxide, Trolox Equivalent Antioxidant Cap-
acity, or C-reactive protein (all p > 0.05).
Dietary data are presented in Table 3. Energy intake
decreased (1857.6±94.4 kcal/day vs. 1601.7±84.7 kcal/day),
as did intake of total fat (66.6±3.8 g/day vs. 54.9±4.7 g/day),
saturated fat (21.0 ± 1.3 g/day vs. 8.4 ± 0.8 g/day), trans
fat (0.9 ± 0.2 g/day vs. 0.2 ± 0.1 g/day), and dietary cho-
lesterol (224.4 ± 21.0 mg/day vs. 12.2 ± 5.1 mg/day) (all
p < 0.05). Fiber intake increased (20.7 ± 1.7 g/day vs.
40.0 ± 2.5 g/day; p < 0.01).
Discussion
Krill oil supplementation
We sought to determine if krill oil supplementation
could maintain HDL-C in individuals following a Daniel
Fast dietary plan for 21 days. This was not the case, as
HDL-C decreased similarly regardless of whether krill
oil or a placebo was consumed. Krill oil supplementation
also did not affect any other outcome measure. Our
findings therefore strongly contradict the work of Bunea
et al. [8], who reported that krill oil supplementation (1–
3 g/day for 90 days) increased HDL-C (43-60%) and
decreased LDL-C (32-39%). On the other hand, our find-
ings support the results of recent investigations [9,12,13]Table 3 Dietary data before and during the final 7 days
of a 21-day Daniel Fast (Mean values and standard error
of mean (SEM), n = 39)
Variable Pre Post p valuea
Energy (kcal) 1857.6 ± 94.4 1601.7 ± 84.7 < 0.01
Protein (g) 79.4 ± 6.2 53.0 ± 3.4 < 0.01
Protein (% energy) 16.7 ± 0.7 13.2 ± 0.5 < 0.01
Carbohydrate (g) 229.2 ± 12.5 240.5 ± 14.1 0.35
Carbohydrate (% energy) 49.5 ± 1.0 60.7 ± 1.7 < 0.01
Fiber (g) 20.7 ± 1.7 40.0 ± 2.5 < 0.01
Sugar (g) 81.6 ± 5.7 73.2 ± 5.2 0.15
Fat (g) 66.6 ± 3.8 54.9 ± 4.7 0.02
Fat (% energy) 32.2 ± 0.8 30.1 ± 1.7 0.25
Saturated Fat (g) 21.0 ± 1.3 8.4 ± 0.8 < 0.01
Monounsaturated Fat (g) 13.7 ± 1.6 18.3 ± 2.7 0.07
Polyunsaturated Fat (g) 6.7 ± 0.5 9.2 ± 1.0 0.01
Trans Fat (g) 0.9 ± 0.2 0.2 ± 0.1 < 0.01
Omega-3 (mg) 0.5 ± 0.1 0.6 ± 0.1 0.81
Omega-6 (mg) 4.8 ± 0.4 6.0 ± 0.9 0.13
Dietary Cholesterol (mg) 224.4 ± 21.0 12.2 ± 5.1 < 0.01
Vitamin C (mg) 64.5 ± 5.6 140.6 ± 11.1 < 0.01
Vitamin E (mg) 5.7 ± 0.8 7.7 ± 0.8 0.03
Vitamin A (RE) 362.0 ± 42.4 485.5 ± 52.1 0.02
Selenium (μg) 46.9 ± 4.9 38.4 ± 9.1 0.35
a p values represent the results of paired t-tests.that found no effect for krill oil supplementation (2 g/
day for 28 days, 1 g/day for 42 days, and 3 g/day for
49 days, respectively) on blood lipids. The baseline LDL-
C values in the Bunea et al. study (165–183 mg/dL) [8]
were considerably larger than the corresponding values
of the other investigations mentioned in this paragraph
(including the present study) [9,12,13]. This may explain
why only Bunea and colleagues [8] found that krill oil
supplementation reduced LDL-C. However, baseline
HDL-C concentrations were similar across studies (also
including the present study) [8,9,12,13], leaving little
scientific explanation for the striking improvement in
this cholesterol noted by Bunea et al. [8]. Due to the in-
ability of krill oil supplementation to affect any outcome
measure in the present study, values for subjects in both
the krill oil and placebo conditions were collapsed and
are discussed as such from this point forward.
Collapsed data
Following a Daniel Fast dietary plan resulted in clinically
significant reductions in LDL-C, the LDL:HDL ratio,
blood glucose, blood insulin, HOMA-IR, systolic BP, and
body weight. This study demonstrates that meaningful
improvements to cardiovascular and glycemic para-
meters can be obtained in response to dietary changes in
only 21 days.
Plant-based diets have consistently been shown to re-
duce LDL-C [14]. The main dietary changes responsible
for this are likely reductions in total fat, saturated fat,
and dietary cholesterol intake, as well as an increase in
fiber intake [14]; each of these dietary changes was
observed in this study. HDL-C decreased in response to
the dietary plan, and decreases in this cholesterol have
been observed in other studies examining vegan diets
[3,6]. A recent investigation found that substituting
monounsaturated fat for carbohydrate within a vegeta-
rian diet increased HDL-C by 12.5% [15]. A similar ap-
proach should be considered for future investigations of
the Daniel Fast.
The reductions in blood glucose, blood insulin, and
HOMA-IR in the present study were not observed in
our previous investigation of the Daniel Fast [6]. Smaller
baseline values for each of the variables in the previous
investigation [6] likely explain these discrepancies. A
trial examining a vegan diet in nondiabetic, overweight
and obese, postmenopausal women noted similar
improvements in blood glucose and blood insulin to
those of the present investigation [4]. Vegan diets have
also been shown to improve glycemic control in indivi-
duals with type 2 diabetes [3,5,16].
The reduction in systolic BP may have been mediated
by an increase in nitric oxide, a signaling molecule that
promotes vasodilation [17]. Support for this claim comes
from our observed 45% increase in the surrogate marker
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increased vegetable consumption (leafy green vegetables
in particular) [18].
There were some limitations associated with this
study. First, the study lacked a control group of subjects
maintaining their usual diet during the 21-day interven-
tion phase. Many prior investigations have demonstrated
that our measured outcome variables experience mi-
nimal to no change in 21 days in the absence of modifi-
cation in dietary habits, exercise habits, or medication
usage. Nonetheless, such changes are possible, and our
failure to include a control group clouds our ability to
determine how much of the changes in our measured
outcome variables were due to dietary changes. Second,
as mentioned above, some subjects were enrolled in the
study despite using medications that may have affected
outcome measures. Finally, the inclusion criteria were
broad, making it difficult to generalize the results of this
investigation.
A key strength of this study is that the observed
changes were of sizeable magnitudes despite occurring
in individuals whose average baseline values for BMI
(25.9 kg/m2), LDL-C (100.6 mg/dL), blood glucose
(101.4 mg/dL), and systolic BP (110.7 mm Hg) did not
differ greatly from healthy norms (< 25.0 kg/m2, <
100 mg/dL, < 100 mg/dL, and < 120 mm Hg respect-
ively). Insofar as healthy individuals have less “room for
improvement”, this suggests that individuals with less-
desirable values for these variables could potentially de-
rive greater clinical benefit from this dietary plan. As
mentioned above, this was observed when the results of
this study were compared to those of our previous inves-
tigation of the Daniel Fast [6] (i.e., the greater improve-
ments in glycemic variables noted in this study were
likely due to less-healthy baseline values). Therefore, it is
important that future trials examining the Daniel Fast
include subject populations that would likely experience
the greatest clinical benefit from this dietary plan, such
as individuals with type 2 diabetes, hyperlipidemia,
hypertension, and/or overweight/obesity.
Conclusion
A Daniel Fast dietary plan improves blood lipids, blood
glucose, blood insulin, HOMA-IR, systolic BP, and body
weight. These improvements were unaffected by krill oil
supplementation, they occurred in only 21 days, and
they occurred in a group of subjects who, on average,
had less room for improvement compared to many dis-
eased populations. Whether following the dietary plan
for a longer duration increases the magnitudes of these
improvements, and whether less-healthy individuals re-
spond more favorably to the dietary plan, are both pre-
sently unknown. These are exciting topics for future
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